NIPH Clinical Trials Search

JRCT ID: jRCT2031210285

Registered date:27/08/2021

Confirmatory study of EN-P09 in patients with enteral tube feeding.

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedPatients with enteral tube feeding
Date of first enrollment05/09/2021
Target sample size110
Countries of recruitment
Study typeInterventional
Intervention(s)Either EN-P09 or control drug is given to patients through a gastrostomy to perform nutritional management for eleven consecutive days.


Primary OutcomeTansthyretin, Retinol-binding protein, Transferrin.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
Include criteria1. Patients receiving enteral feeding via a gastrostomy into the stomach. 2. Patients able to stay at the study site from the day before the start of the run-in observation period until completion of post-dosing examination. 3. Patients aged 20 years old or more. 4. Patients or the legal representative capable of giving informed consent in wrtiting to participate in the study of their own free will.
Exclude criteria1. Patients with a history of hypersensitivity to any ingredients of study drugs. 2. Patients with a history of allergy to milk protein. 3. Patients with no residual gastric or intestinal function. 4. Patients with ileus. 5. Patients with severe liver or renal dysfunction (example: acute or chronic renal failure, or cirrhosis). 6. Patients with abnormalities in carbohydrate metabolism including severe diabetes mellitus. 7. Patients with congenital abnormalities in amino acid metabolism. 8. Patients with severe heart disease (example: myocardial infarction), severe hematological disorder (example: aplastic anemia), inflammatory bowel disease, pneumonia, serious diarrhea (example: frequent watery diarrhea), and patients with malignant tumor. 9. Patients with a history of resection of esophagus or stomach, except for minimally invasive surgery such as endoscopic submucosal dissection. 10. Patients with a history of resection of intestines within 1 year before obtaining informed consent , except for slight removal like polyp or appendectomy. 11. Patients with difficulties in taking required amount of blood sample for clinical trial. 12. Patients participated in other clinical trials within 24weeks before obtaining informed consent. 13. Patients who are judged by investigator to be excluded.

Related Information


Public contact
Name Tadahiro Kan
Address Nikko Kanda Bldg. 6F, 1-1 Kanda-Ogawamachi, Chiyoda-ku, Tokyo Tokyo Japan 101-0052
Telephone +81-3-6632-3516
Affiliation EN Otsuka Pharmaceutical Co., Ltd.
Scientific contact
Name Michio Maruyama
Address 3-6-1, Midoricho, Nishitokyo Shi, Tokyo Tokyo Japan 188-0002
Telephone +81-3-6632-3516
Affiliation Tanashi Hospital